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Although potential arthropod vectors are abundant in
Cameroon, acute febrile illnesses are rarely evaluated for
arboviral or rickettsial infections. Serum samples from 234
acutely febrile patients at clinics in Tiko and Buea,
Cameroon, were examined for antibodies to Rickettsia
africae and African alphaviruses and flaviviruses. These
serum samples did not contain antibodies against typhoid,
and blood malarial parasites were not detected. Serum
samples of 32% contained immunoglobulin M antibodies
reactive with R. africae by immunofluorescence assay and
were reactive with outer membrane proteins A and B of R.
africae by immunoblotting. These findings established a
diagnosis of acute rickettsiosis, most likely African tick-bite
fever. Hemagglutination inhibition testing of the serum sam-
ples also detected antibodies to chikungunya virus (47%)
and flaviviruses (47%). High prevalence of antibodies to
arboviruses may represent a major, previously unrecog-
nized public health problem in an area where endemic
malaria and typhoid fever have been the principal diagnos-
tic considerations. 
C
ameroon is situated 2°–14° north of the equator; it has
a vast tropical rain forest located 2°–5° north of the
equator, which provides a good habitat for a variety of
hematophagous arthropods. Vector-borne bacterial and
viral diseases are rarely considered by local clinicians,
whose primary diagnostic focus is on endemic malaria and
typhoid fever. Chikungunya fever is an arboviral disease
transmitted by mosquitoes of the genus Aedes; it occurs in
neighboring Nigeria; and epidemics have been reported in
Angola, Burundi, the Central African Republic, Kenya,
Namibia, Senegal, South Africa, Tanzania, Uganda, and
Zimbabwe (1–3). Antibodies to chikungunya virus
(CHIKV) also were observed in German aid workers who
had served in Bénin, Burkina Faso, and Zambia (4). The
extent of CHIKV infection in the human population of
Cameroon is unknown. 
Aedes aegypti and A. albopictus, the major vectors of
dengue fever, are both present in Cameroon (5,6).
Although no information is available on the prevalence of
dengue fever in Cameroon, epidemics of the disease have
been reported in other neighboring African countries.
Epidemic dengue hemorrhagic fever has not been reported
in Africa, but sporadic cases clinically compatible with it
have been reported in Mozambique and Djibouti (7).
Yellow fever is endemic in much of sub-Saharan Africa,
and large outbreaks of the disease have been reported in
Ethiopia, Senegal, Nigeria, and Guinea (8,9). Although
epidemics of yellow fever have not been reported in
Cameroon, it is nonetheless considered to be a high-risk
zone for the disease (8). Currently, no immunization pro-
grams are in place in the country to prevent yellow fever.
Febrile illnesses such as chikungunya fever, dengue fever,
and nonicteric yellow fever can be difficult to recognize,
especially during the early stages of the disease and in a
malaria-endemic zone (2). 
Rickettsia africae is a spotted fever group rickettsia
transmitted by Amblyomma ticks (10). It is endemic in
some southern African countries, such as Zimbabwe and
South Africa; most cases are reported in travelers returning
from these countries (11,12). Although serologic surveys
in Angola, Burkina Faso, Central African Republic,
Congo, Ivory Coast, Mali, and Zimbabwe have previously
detected antibodies to spotted fever group rickettsiae, the
first human case of R. africae infection was not reported
until 1992 (13–15). An earlier serologic survey that used a
method less reliable than the immunofluorescent antibody
assay demonstrated rickettsial antibodies in cattle and
humans in the northern region of Cameroon and in other
animals in the south of the country (16,17). Since then, lit-
tle has been done to determine the incidence of rickettsios-
es in Cameroon. In this study, we sought to detect
antibodies to spotted fever group rickettsiae, CHIKV, yel-
low fever, dengue, West Nile, and Spondweni viruses in
serum samples collected from patients with symptoms of
an acute febrile illness seen at clinics in the South West
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Materials and Methods
Study Population
A total of 234 serum samples were obtained at the
Cameroon Development Corporation Central Clinic in Tiko
(180 samples) and the Mount Mary Health Center in Buea
(54 samples) from February 15 to March 31, 2001, from
patients with clinical symptoms of a febrile illness and lab-
oratory test results that excluded a diagnosis of malaria or
typhoid fever. The samples were collected into sterile con-
tainers, and the serum samples were stored at –20°C. One
hundred forty-two samples were from female patients, and
92 were from male patients; most samples were from adults
(Table 1). The study participants were all residents of the
South West Province of Cameroon from locations along the
Atlantic Coast (Figure 1): Buea (4° 9′ N, 9° 13′ E), 52
patients; Limbe (4° 1′ N, 9° 12′ E), 27 patients; Muyuka (4°
10′ N, 9° 25′ E), 22 patients; and Tiko (4° 2′ N, 9° 19′ E),
133 patients. Yellow fever vaccine has not been adminis-
tered routinely or in response to disease outbreaks in this
region. The research protocol was approved by the
Cameroon Ministry of Health and the administration of the
clinics to ensure the ethical conduct of the study.
Immunofluorescence Assay 
Immunofluorescence assays (IFAs) were performed to
detect antibodies to R. africae and R. conorii, as previous-
ly reported (18). Serial twofold dilutions (1 of 32 to 1 of
4,096) of human serum were prepared in phosphate-
buffered saline (PBS) containing 1% bovine serum albu-
min (BSA) and 0.1% Tween 20. Antigen slides were
blocked in PBS containing 1% BSA and 0.01% sodium
azide. Ten microliters of each serum dilution was added to
each well of the antigen slide and incubated for 30 min at
37°C in a humidity chamber. The slides were subsequent-
ly rinsed with a stream of PBS containing 0.1% Tween and
then washed twice more in the same solution for 10 min.
Fluorescein isothiocyanate–conjugated goat anti-human
immunoglobulin (Ig) A, IgG, and IgM immune serum
(KPL Inc., Gaithersburg, MD), 10 µL diluted 1 to 100 in
PBS containing 1% BSA and 0.01% Tween 20, was added
to each well and incubated in a humidity chamber for 30
min at 37°C. The slides were washed once in PBS contain-
ing 0.1% Tween 20 for 10 min and once with PBS contain-
ing 0.1% Tween 20 and 0.01% Evans blue for 10 min. The
rinsed slides were blot dried, mounted with gel mount
(Biomeda Corp, Foster City, CA) and observed under a
fluorescence microscope at 400x magnification. Serum
samples yielding distinctly fluorescent rickettsiae at a 1 to
64 dilution or higher were considered positive.
For assaying IgM antibody to R. africae and  R.
conorii, IgG was removed from IgG/IgA/IgM–positive
serum by using recombinant protein G (MiniRapiSepM,
PanBio, InDx, Baltimore, MD) according to the manufac-
turer’s instructions. Serum samples with specific fluores-
cence at >1:32 dilution were considered positive. Serial
twofold dilutions of serum were tested to determine the
endpoint titer.
Western Immunoblot Assay 
R. africae and R. conorii were released from Vero cell
components by sonication and purified by density gradient
centrifugation. Proteins were examined for immunoreac-
tivity with the Cameroonian sera by Western immunoblot-
ting (19,20).
Preparation of Arbovirus Antigens
Arbovirus antigens were produced by sucrose-acetone
extraction (21) of brains from newborn mice inoculated
intracerebrally with the following arboviruses: CHIKV
(Bili 4 strain), o’nyong-nyong virus (ONNV) (MP 30),
yellow fever virus (17D), dengue 1 virus (Mochizuki
strain), dengue 2 virus (New Guinea C), dengue 3 virus
(H87), dengue 4 virus (H-241), West Nile virus (NY
385/99), and Spondweni virus (SAAR94). All arboviruses
were obtained from the Arbovirus Reference Center at the
University of Texas Medical Branch.
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Table 1. Distribution of febrile Cameroonian patients in this study 
according to age and sex 
Age group (y)  Female  Male  Total 
<5  2  2  4 
6–20  13  10  23 
>21  127  80  207 
Total   142  92  234 
Figure 1. Location of townships in South West Province of
Cameroon where samples were obtained.
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Hemagglutination-inhibition (HI) tests were performed
by using a microtechnique described previously (21).
Before being tested, serum samples were treated with ace-
tone to remove nonspecific inhibitors, and then goose ery-
throcytes were added to absorb natural agglutinins.
CHIKV and ONNV antigens were tested at pH 6.2; dengue
1, 2, and 3 and yellow fever viruses were tested at pH 6.4;
and dengue 4, West Nile, and Spondweni viruses were test-
ed at pH 6.6. For the HI test, 4–8 U of antigen was used.
Titers were recorded as the highest dilutions causing com-
plete or almost complete inhibition of hemagglutination.  
Complement Fixation Test
Complement fixation (CF) tests were performed
according to a microtechnique modified from Fulton and
Dumbell (22), using 2 full U of guinea pig complement
and the sucrose-acetone–extracted CHIKV and ONNV
antigens described earlier. Serum samples were incubated
at 60°C for 20 min before testing. Titers were recorded as
the highest dilution giving 3+ or 4+ fixation of comple-
ment on a scale of 0 to 4+ (0 = complete hemolysis and 4+
= no hemolysis).
Results
Serologic Testing for Rickettsial Antibodies
The 234 serum samples initially were screened by IFA
for IgG, IgA, and IgM antibodies against R. africae and R.
conorii; the samples containing antibodies at a titer of 32
were examined by the IgM-specific IFA. The results indi-
cated that 75 patients (32.1%) had IgM antibodies reactive
with  R. africae. Fifty-one (35.9%) of the 142 female
patients had IgM antibodies against R. africae; and 24
(26.1%) of the male patients had IgM anti–R. africae anti-
bodies. The distribution of endpoint IgM titers for R.
africae was 32 (24%), 64 (18%), 128 (20%), 256 (14.4%),
512 (12%), 1,024 (8%), and 2,048 (2.7%).
The distribution of IgM titers against R. conorii among
the 75 R. africae–positive serum samples was 32 (29.3%),
64 (32.8%), 128 (17.2%), 256 (19%), and 512 (1.7%).
Twenty-six of the samples had antibody titer fourfold or
greater for R. africae than for R. conorii. None of the
serum samples had titers fourfold higher for R. conorii.
Nineteen serum samples had antibody titers twofold high-
er for R. africae; three had antibody titers twofold higher
for R. conorii. Eight serum samples had a titer of 32 for R.
africae and were negative for R. conorii. Nineteen samples
had the same titers for R. africae and R. conorii. Of the
patients with IgM antibodies to spotted fever group rick-
ettsiae, 67 (89%) were adults, and 8 (11%) were <20 years
of age. None of four children <5 years of age had IgM anti-
bodies to R. africae. Western immunoblot analysis con-
firmed the IFA results (Figure 2). The reactive serum sam-
ples contained antibodies that were immunoreactive with
both OmpA and OmpB of R. africae.
Serologic Testing for Arboviral Antibodies 
HI testing of serum samples from febrile patients in
South West Province demonstrated antibodies to CHIKV,
dengue 1–4, yellow fever, West Nile, and Spondweni viral
antigens (Table 2). Antibodies were detected in some of the
serum samples for all of the viruses tested, and consider-
able cross-reactivity among the flaviviruses was observed.
The HI tests with dengue 1–4 viruses and yellow fever
virus antigens yielded similar results; titers ranged from 20
to 2,560. HI antibodies to CHIKV antigen were detected in
103 (44%) of the 234 serum samples, and a titer of >1,280
was observed in 11 samples. Comparative CF testing
demonstrated that the endpoint titers were higher against
CHIKV antigen than ONNV antigen, a finding that sug-
gests that CHIKV was the infecting alphavirus.
Eighty-four (35.9%) of the 234 serum samples con-
tained HI antibodies reactive with one or more of the
dengue 1–4 viruses, 93 (39.7%) had antibodies to yellow
fever virus, 62 (26.5%) contained antibodies against West
Nile virus, and 65 (27.8%) had antibodies to Spondweni
virus. In all, 110 (47%) of the serum samples contained
antibodies to one or more of the flaviviruses. Antibodies to
CHIKV and the flaviviruses were detected in patients from
each of the study locations (Table 2).
Discussion
In Cameroon, as in many other African countries, rick-
ettsioses and arboviral infections are rarely considered
when evaluating patients with acute, undifferentiated febrile
illnesses. This situation can be attributed in part to unavail-
ability of specific laboratory tests, equipment, and expertise
and also the limited economic resources in many countries
of the region. In Cameroon, most patients are evaluated by
clinical laboratory methods only for malaria and typhoid
fever. Since many patients with rickettsial and arboviral ill-
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Figure 2. Immunoblot of Rickettsia africae antigens with R. africae-
positive and -negative patient serum samples. Lanes 1-3: R.
africae-positive patients' serum samples; lanes 4-5: R. africae-
negative patients' serum samples; lane 6: anti-OmpA monoclonal
antibody; lane 7: anti-OmpB monoclonal antibody. nesses initially have acute febrile syndromes, their diagno-
sis is difficult without confirmatory laboratory tests. 
Previous retrospective serologic surveys detected anti-
bodies to rickettsiae in Zimbabwe, Ivory Coast, Central
African Republic, and Egypt (15,23–26). However, detect-
ing IgM antibodies to rickettsiae by IFA, in association
with febrile illness, is a better approach to identifying
recent or current infections; Western immunoblot assay
can be used to confirm positive IFA results. 
Our results indicate that one or more rickettsioses are
endemic in Cameroon. Most previous serologic surveys
have detected antibodies in healthy study participants
(14,17,18,26,27); however, our study population was
composed of patients with acute febrile illnesses other
than malaria or typhoid fever. The specific cause of the
agent that stimulated the antibodies to spotted fever group
rickettsiae in these patients remains to be determined.
Raoult et al. (11) reported spotted fever rickettsiosis in
travelers returning to Europe from Africa with documen-
tation of R. africae infections by isolation of the agent and
specific polymerase chain reaction results. The same
authors also evaluated serologic methods to distinguish
between infection with R. africae and  R. conorii; they
reported that a fourfold or greater titer to R. africae by
IFA had a specificity of 100% but a sensitivity of only
26% (11). This criterion supported the diagnosis of R.
africae infection in 26 (35%) of the 75 patients in our
study with acute rickettsiosis and did not establish a diag-
nosis of R. conorii infection in any patient. Our
immunoblot detection of antibodies to R. africae OmpA
and OmpB also supported the diagnosis of R. africae
infection rather than R. conorii. However, cross-reactivity
of the antibodies with OmpA of another rickettsial organ-
ism that was not included in the study, including any
undiscovered rickettsiae, is possible. Raoult et al. (11)
have diagnosed R. africae infections in individual travel-
ers whose infections were acquired in nearby Central
African Republic and Gabon. Although our findings sug-
gest that the infections in Cameroonian patients were
caused by R. africae, the possibility of the occurrence of
another spotted fever group rickettsial infection cannot be
excluded because spotted fever group rickettsiae share
closely related antigens. Moreover, the most reliable and
specific method to establish the identity of the causative
agent is isolating it from the blood or tissue of suspected
patients; this remains to be achieved in Cameroon. Other
problems that need to be addressed include a full descrip-
tion of the clinical spectrum of this rickettsiosis in African
patients, the risk factors for severe illness, the vector(s),
natural history of the bacterium, and epidemiology of the
disease.
After an incubation period averaging 6–7 days, R.
africae–infected travelers returning to Europe and North
America manifested an influenza-like syndrome including
fever (88%), myalgia (63%), eschars (95%), regional lym-
phadenopathy (43%), and rash (46%) in one series (11). A
subsequent series of Norwegian travelers to sub-equatorial
Africa had a similar syndrome of fever, headache, and
myalgia but with a lower proportion of patients with an
eschar (53%) (28). The low proportion of children in our
study suggests that severity of the clinical manifestations
may be age-dependent, as has been documented for Rocky
Mountain spotted fever and louse-borne typhus fever (29).
To date, African tick-bite fever has been characterized as a
mild illness.  However, the presence of glucose-6-phos-
phate dehydrogenase deficiency and the empiric treatment
of the febrile illness with sulfonamide antimicrobials, both
frequent situations in Africa, might result in more severe
disease; this possibility needs to be evaluated (30–33). It
could be predicted that A. variegatum might transmit R.
africae, and that Rhipicephalus species would transmit R.
conorii; but the susceptibility of other ticks in Cameroon to
these rickettsiae has not been studied. The unexpectedly
high incidence of spotted fever rickettsiosis in this popula-
tion also suggests that the course of illness in many febrile
patients in Cameroon might be ameliorated by early treat-
ment with an antirickettsial drug such as doxycycline.
CHIKV infection is common in sub-Saharan Africa;
antibodies to CHIKV have frequently been detected during
serosurveys throughout the humid forest and semi-arid
savannas of Africa (1,2,34–36). Although CHIKV and
ONNV are closely related (34), our serum samples contain-
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Table 2. Geographic origin of 234 Cameroonian patients with antibodies to chikungunya, yellow fever, dengue, West Nile, and 
Spondweni viruses
a 
Antigen  Buea (n = 52)  Limbe (n =27)  Muyuka (n = 22)  Tiko (n = 133)  Total  Geometric mean titer
b 
Chikungunya  15  18  5  65  103  250 
Yellow fever  12  10  4  67  93  56 
Dengue 1  5  11  5  59  80  91 
Dengue 2  6  9  5  55  75  66 
Dengue 3  6  6  3  41  56  71 
Dengue 4  4  6  3  42  55  85 
West Nile  0  9  2  51  62  71 
Spondweni  0  9  3  53  65  77 
aAs detected by hemagglutination inhibition test.  
bReciprocal of titers. ing antibodies to alphaviruses yielded much lower titers
against the ONNV antigen, suggesting that cross-reactivity
was at a low level and that CHIKV was the circulating
agent. Chikungunya fever is characterized by fever,
headache, nausea, vomiting, myalgia, rash, and arthralgia
(35). These clinical symptoms are similar to those of
dengue viral infection and can lead to misdiagnosis (37).
Evidence suggests that CHIKV circulates continually in
sylvatic cycles in Africa; the virus has been isolated from
forest-dwelling mosquitoes in several African countries
including Senegal, Ivory Coast, and South Africa (35,36). 
Dengue fever is endemic in tropical and subtropical
regions worldwide. The possibility that Cameroon is
another dengue-endemic region would not be surprising.
This infection, which usually manifests as undifferentiated
fever, can lead to hospitalization of large numbers of peo-
ple. Outbreaks cause illness and death rates with substan-
tial socioeconomic impact. The results of our study
indicate that rickettsial and arboviral infections are com-
mon among residents of Cameroon and that local health
personnel should include them in their differential diagno-
sis. For both the arboviral and rickettsial agents, much
work remains to be done, particularly identification of the
viruses and rickettsiae in patients and arthropods.
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